iShares Biotechnology ETF
428 hedge funds and large institutions have $3.72B invested in iShares Biotechnology ETF in 2016 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 149 increasing their positions, 122 reducing their positions, and 52 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
5% less funds holding in top 10
Funds holding in top 10: 21 → 20 (-1)
55% less call options, than puts
Call options by funds: $629M | Put options by funds: $1.39B
Holders
428
Holding in Top 10
20
Calls
$629M
Puts
$1.39B
Top Buyers
| 1 | +$130M | |
| 2 | +$127M | |
| 3 | +$79.5M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$50.6M |
| 5 |
SG Americas Securities
New York
|
+$45.3M |
Top Sellers
| 1 | -$157M | |
| 2 | -$142M | |
| 3 | -$128M | |
| 4 |
LPL Financial
San Diego,
California
|
-$71M |
| 5 |
Jane Street
New York
|
-$69.1M |